Upgrade to SI Premium - Free Trial

FDA grants priority review to Genentech's Gazyva for kidney disease

July 15, 2026 1:01 AM
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), said the U.S. Food and Drug Administration has ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA